Skip to Main Content

Paper Details

Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma.
Clin Lung Cancer
16
2019
AXL, Cabozantinib, KRAS, KRAS mutations, MET, NSCLC, Non-small-cell Lung Carcinoma, PATIENTS, Patients, RET, ROS1, asthenia, cabozantinib, diarrhea, fatigue, growth factor receptor, hemorrhage, hypertension, non-small-cell lung carcinoma, palmar-plantar erythrodysesthesia, patients, tumor, tyrosine, tyrosine kinase, vascular endothelial growth factor receptor 2
Author NameAffiliation
Harriet M KlugerYale Cancer Center
Harriet M KlugerYale Cancer Center
Primo N LaraUniversity of California davis
  • 1 - 3

Datasets

Release 1.2